ArticleBMC cardiovascular disorders2026
Apparent treatment-resistant hypertension in ambulatory hypertensive patients in Northeast Ethiopia: prevalence, treatment patterns, and predictors.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApparent treatment-resistant hypertension (aTRH) significantly contributes to the rising prevalence of uncontrolled hypertension in Africa, leading to serious cardiovascular and cerebrovascular risks. Despite its critical importance, comprehensive, evidence-based data on aTRH in sub-Saharan Africa, including Ethiopia, remains scarce. The Northeast Amhara region has been particularly underexplored in this regard. This study aimed to assess the prevalence, treatment pattern, and predictors of aTRH among ambulatory adult hypertensive patients attending hypertension clinics in Dessie Comprehensive Specialized Hospital (DCSH) and Boru Meda General Hospital (BMH) in Northeast Ethiopia.
methodsA multi-center cross-sectional study was conducted from February 1 to July 30, 2024, involving 240 hypertensive patients (192 from DCSH and 48 from BMH) who were on at least one antihypertensive medication. Patients were selected using a multistage sampling (stratified proportional, followed by simple random sampling) method. Data was collected through rigorous medical record reviews, and descriptive statistics were used for data summarization. The study followed the latest (2018) AHA guideline definition to affirm aTRH, targeting goal blood pressure (BP) of < 130/80 mmHg. Logistic regression analysis identified factors associated with aTRH, with statistical significance set at p < 0.05.
resultsaTRH was observed in 9.2% of patients. About 48.3% were on dual antihypertensive therapy, with calcium channel blockers (65.4%), diuretics (60.4%), and angiotensin-converting enzyme inhibitors (60.0%) being the most common medications. Individual medications most frequently prescribed included amlodipine (62.9%), enalapril (60.0%), and hydrochlorothiazide (44.6%). Over half of the patients (56.2%) had poorly controlled BP at the last follow-up. At least one-time change in antihypertensive regimens was the sole predictor of aTRH (Adjusted Odds Ratio [AOR]: 2.85, 95% CI: 1.14–7.10, p = 0.025).
conclusionaTRH is notably prevalent in the region, significantly exacerbating the overall burden of uncontrolled hypertension in Ethiopia. Encountering at least one-time antihypertensive regimen change is positively associated with aTRH. To mitigate the dire impact of aTRH, it is crucial to implement targeted interventions, including optimizing treatment strategies, improving adherence, and addressing factors contributing to resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.